161 related articles for article (PubMed ID: 35013582)
1. PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice.
de Jong LM; Zhang Z; den Hartog Y; Sijsenaar TJP; Martins Cardoso R; Manson ML; Hankemeier T; Lindenburg PW; Salvatori DCF; Van Eck M; Hoekstra M
Sci Rep; 2022 Jan; 12(1):483. PubMed ID: 35013582
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice.
Hoekstra M; Nahon JE; de Jong LM; Kröner MJ; de Leeuw LR; Van Eck M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1402-1409. PubMed ID: 30776415
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of protein arginine methyltransferase 3 activity selectively impairs liver X receptor-driven transcription of hepatic lipogenic genes in vivo.
Nahon JE; Groeneveldt C; Geerling JJ; van Eck M; Hoekstra M
Br J Pharmacol; 2018 Aug; 175(15):3175-3183. PubMed ID: 29774529
[TBL] [Abstract][Full Text] [Related]
4. Decreased nitric oxide content mediated by asymmetrical dimethylarginine and protein l-arginine methyltransferase 3 in macrophages induces trophoblast apoptosis: a potential cause of recurrent miscarriage.
Hao F; Tang LC; Sun JX; Li WX; Zhao Y; Xu XH; Jin LP
Hum Reprod; 2021 Nov; 36(12):3049-3061. PubMed ID: 34647126
[TBL] [Abstract][Full Text] [Related]
5. 8-HEPE-Concentrated Materials from Pacific Krill Improve Plasma Cholesterol Levels and Hepatic Steatosis in High Cholesterol Diet-Fed Low-Density Lipoprotein (LDL) Receptor-Deficient Mice.
Saito M; Ishida N; Yamada H; Ibi M; Hirose M
Biol Pharm Bull; 2020; 43(6):919-924. PubMed ID: 32475913
[TBL] [Abstract][Full Text] [Related]
6. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3).
Kaniskan HÜ; Szewczyk MM; Yu Z; Eram MS; Yang X; Schmidt K; Luo X; Dai M; He F; Zang I; Lin Y; Kennedy S; Li F; Dobrovetsky E; Dong A; Smil D; Min SJ; Landon M; Lin-Jones J; Huang XP; Roth BL; Schapira M; Atadja P; Barsyte-Lovejoy D; Arrowsmith CH; Brown PJ; Zhao K; Jin J; Vedadi M
Angew Chem Int Ed Engl; 2015 Apr; 54(17):5166-70. PubMed ID: 25728001
[TBL] [Abstract][Full Text] [Related]
7. Liver-selective γ-secretase inhibition ameliorates diet-induced hepatic steatosis, dyslipidemia and atherosclerosis.
Kim K; Yu J; Kang JK; Morrow JP; Pajvani UB
Biochem Biophys Res Commun; 2020 Jul; 527(4):979-984. PubMed ID: 32439159
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio.
Wiśniewska A; Stachowicz A; Kuś K; Ulatowska-Białas M; Totoń-Żurańska J; Kiepura A; Stachyra K; Suski M; Gajda M; Jawień J; Olszanecki R
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639029
[TBL] [Abstract][Full Text] [Related]
9. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
Mulvihill EE; Assini JM; Sutherland BG; DiMattia AS; Khami M; Koppes JB; Sawyez CG; Whitman SC; Huff MW
Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):742-8. PubMed ID: 20110573
[TBL] [Abstract][Full Text] [Related]
10. Myeloid cell-specific ATP-binding cassette transporter A1 deletion has minimal impact on atherogenesis in atherogenic diet-fed low-density lipoprotein receptor knockout mice.
Bi X; Zhu X; Gao C; Shewale S; Cao Q; Liu M; Boudyguina E; Gebre AK; Wilson MD; Brown AL; Parks JS
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1888-99. PubMed ID: 24833800
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.
Kassel KM; Sullivan BP; Cui W; Copple BL; Luyendyk JP
Am J Pathol; 2012 Oct; 181(4):1287-95. PubMed ID: 22841818
[TBL] [Abstract][Full Text] [Related]
12. Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice.
Hoekstra M; Lammers B; Out R; Li Z; Van Eck M; Van Berkel TJ
Mol Pharm; 2009; 6(1):182-9. PubMed ID: 19183106
[TBL] [Abstract][Full Text] [Related]
13. PRMT5 inhibition induces pro-inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice.
Zhang Y; Verwilligen RAF; Van Eck M; Hoekstra M
J Cell Mol Med; 2023 Apr; 27(8):1056-1068. PubMed ID: 36946061
[TBL] [Abstract][Full Text] [Related]
14. Aortic cholesterol accumulation correlates with systemic inflammation but not hepatic and gonadal adipose tissue inflammation in low-density lipoprotein receptor null mice.
Wang S; Miller B; Matthan NR; Goktas Z; Wu D; Reed DB; Yin X; Grammas P; Moustaid-Moussa N; Shen CL; Lichtenstein AH
Nutr Res; 2013 Dec; 33(12):1072-82. PubMed ID: 24267047
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor antagonist exacerbates dyslipidemia in mice.
Amano Y; Yamakawa H; Yonemori K; Shimada M; Tozawa R
Pharmacol Rep; 2018 Feb; 70(1):172-177. PubMed ID: 29367104
[TBL] [Abstract][Full Text] [Related]
16. Oxidized fatty acids promote atherosclerosis only in the presence of dietary cholesterol in low-density lipoprotein receptor knockout mice.
Khan-Merchant N; Penumetcha M; Meilhac O; Parthasarathy S
J Nutr; 2002 Nov; 132(11):3256-62. PubMed ID: 12421837
[TBL] [Abstract][Full Text] [Related]
17. Asymmetrical methyltransferase PRMT3 regulates human mesenchymal stem cell osteogenesis via miR-3648.
Min Z; Xiaomeng L; Zheng L; Yangge D; Xuejiao L; Longwei L; Xiao Z; Yunsong L; Ping Z; Yongsheng Z
Cell Death Dis; 2019 Aug; 10(8):581. PubMed ID: 31378783
[TBL] [Abstract][Full Text] [Related]
18. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice.
Sberna AL; Assem M; Xiao R; Ayers S; Gautier T; Guiu B; Deckert V; Chevriaux A; Grober J; Le Guern N; Pais de Barros JP; Moore DD; Lagrost L; Masson D
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2232-9. PubMed ID: 21778422
[TBL] [Abstract][Full Text] [Related]
19. Hepatic FOXA3 overexpression prevents Western diet-induced obesity and MASH through TGR5.
Gopoju R; Wang J; Pan X; Hu S; Lin L; Clark A; Xu Y; Yin L; Wang X; Zhang Y
J Lipid Res; 2024 Apr; 65(4):100527. PubMed ID: 38447926
[TBL] [Abstract][Full Text] [Related]
20. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
